446
Participants
Start Date
January 31, 1999
Primary Completion Date
September 30, 2000
Study Completion Date
September 30, 2000
Placebo
Subjects were randomized to one of the 3 treatment groups (eletriptan 40 mg, eletriptan 80 mg, or placebo) in a 2:2:1 ratio and were given sufficient medication to treat 3 migraine attacks (including a second dose for each attack for recurrence) within 18 weeks of the initial visit. Subjects were instructed to treat a moderate to severe migraine within 6 hours of the onset of pain provided the headache was not decreasing in severity, the aura phase had ended and they had taken no analgesic or antiemetic within 6 hours. Efficacy data was collected in a diary. Subjects were allowed to take rescue medication if they had no response to the study medication within 4 hours of onset.
Eletriptan 40 mg
Subjects were randomized to one of the 3 treatment groups (eletriptan 40 mg, eletriptan 80 mg, or placebo) in a 2:2:1 ratio and were given sufficient medication to treat 3 migraine attacks (including a second dose for each attack for recurrence) within 18 weeks of the initial visit. Subjects were instructed to treat a moderate to severe migraine within 6 hours of the onset of pain provided the headache was not decreasing in severity, the aura phase had ended and they had taken no analgesic or antiemetic within 6 hours. Efficacy data was collected in a diary. Subjects were allowed to take rescue medication if they had no response to the study medication within 4 hours of onset.
Eletriptan 80 mg
Subjects were randomized to one of the 3 treatment groups (eletriptan 40 mg, eletriptan 80 mg, or placebo) in a 2:2:1 ratio and were given sufficient medication to treat 3 migraine attacks (including a second dose for each attack for recurrence) within 18 weeks of the initial visit. Subjects were instructed to treat a moderate to severe migraine within 6 hours of the onset of pain provided the headache was not decreasing in severity, the aura phase had ended and they had taken no analgesic or antiemetic within 6 hours. Efficacy data was collected in a diary. Subjects were allowed to take rescue medication if they had no response to the study medication within 4 hours of onset.
Sentralsykehuset I Akershus, Nordbyhagen
Bispebjerg Hospital, Copenhagen
Kas Glostrup, Glostrup Municipality
Strandquist, Dr. Stein Bror, Tønsberg
Hilleroed Sygehus, Hilleroed
Neubauer, Ole (Private Practice), Nykoebing F
Korsgaard, Anne G. (Private Practice), Odense C
Centralsygehuset I Esbjerg, Esbjerg
Arhus Kommunehospital, Arhus C
Knud Kjaersgaard Pedersen, Hjørring
Turku Headache Centre, Turku
Medicin Kliniken, Universitetssjukhuset, Lund
Neuro Kliniken, Helsingborg, Helsingborg
Porin Laakarikeskus, Pori
Torikeskuksen Laakariasema, Jyväskylä
Mikkelin Paansarkypoliklinikka (Mikkeli Headache), Mikkeli
Haukiputaan Laakarikeskus, Haukipudas
Helsinki University Central Hospital, Helsinki
Hyvinkaa District Hospital, Hyvinkää
Bosch Medicentrum (Locatie Willem Alexander Ziekenhuis), 's-Hertogenbosch
Sint Lucas Andreas Ziekenhuis (Location: St.Lucas), Amsterdam
Private Practice, Oyvind Rosjo, Oslo
Volvat Medisinske Senter, Oslo
Migranklinik-Goeteborg, Gothenburg
Neurologsektionen, Lasarettet, Helsingborg
Medicin Kliniken, Sjukhuset, Kristinehamn
St Gorans Sjukhus, Stockholm
Kronobergskliniken, Vaxjo
Danderydssjukhus
Foretagshalsovarden Linden
Fylkessjukehuset I Molde
Huslakargruppen
Lakarhuset Hermelinen
Lakarhuset
Limhamns Lakargrupp, Tarnan
Lundsbysjukhus
Medicinskt Centrum
Nijmeegs Interkonfessioneel Ziekenhuis Canisius-Wilhelmina
Primarvarden
Regionsykehuset I Trondheim
Sentralsjukehuset I Hedmark
Sint Anna Ziekenhuis
Vardcentralen
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
INDUSTRY